Head-to-head · Cost-Efficiency Index
Found vs MyDrHank
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Found
Insured shoppers willing to prepay 12 months upfront to reach the lowest advertised rate, who also want behavior-change coaching bundled in.
Visit FoundMyDrHank
Needle-averse shoppers who want a daily semaglutide tablet, have decided a twelve-month commitment is acceptable, and value a price that never moves as the dose climbs more than a low sticker.
Visit MyDrHankThe verdict
Found takes it, leading the Cost-Efficiency Index 88 to 65. A real insurance-billing pathway on both molecules — but the widely-quoted $99/mo headline requires an insurance plan AND a full year prepaid upfront; the true no-commitment rate is $199-289/mo. MyDrHank still earns a C — Needle-averse shoppers who want a daily semaglutide tablet, have decided a twelve-month commitment is acceptable, and value a price that never moves as the dose climbs more than a low sticker.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs Found.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Found | MyDrHank |
|---|---|---|
| Cost-Efficiency Index | 88/100 | 65/100 |
| Semaglutide / mo | $199/mo (insurance-linked) | $249/mo oral, $259/mo injectable (yearly prepay: $171 / $178) |
| Tirzepatide / mo | $199/mo (insurance-linked) | $349/mo month-to-month ($240/mo only on a year prepaid) |
| Semaglutide / yr (modeled) | $2,388 | $2,988 |
| Tirzepatide / yr (modeled) | $2,388 | $4,188 |
| Coverage | All 50 states | Not published; program excludes KS, LA, MS, NM, ND, WV |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank on the board | #7 | #108 |
Found
88/100Where the value is
- Genuine insurance-billing pathway, unlike most cash-only compounded competitors — most members reportedly pay under $30/visit
- Nationwide
- Strong behavior-change program adds value
The tradeoffs
- The advertised '$99/mo' headline requires BOTH an insurance-linked plan AND a 12-month prepay at once — the real month-to-month rate is $199/mo (insured) or $289/mo (cash-pay), 2-3x the headline
- Coaching subscription can't be unbundled, which reduces contract flexibility
MyDrHank
65/100Where the value is
- The price does not change as your dose is titrated up — its FAQ states it plainly ("The price stays the same at every dose — no surprise price increases"), and dose-indexed pricing is the single most common way a cheap first month becomes an expensive fourth one
- A genuine oral route on semaglutide: a daily tablet, including one compounded with low-dose ondansetron specifically to blunt the nausea that ends most GLP-1 courses early
- The entire price ladder is public — monthly, quarterly, 6-month and yearly, with the total for each term printed beside the per-month figure — before any quiz, intake or email capture
The tradeoffs
- EVERY price the site advertises is a twelve-month prepay rate, and not by accident: the price display is coded to return the cheapest term in the ladder, so "From $X/mo" is always the yearly figure. No page shows a month-to-month rate beside it
- What the twelve months actually cost, up front: oral semaglutide $2,057 to reach the advertised $171/mo, injectable semaglutide $2,140 to reach $178/mo, and tirzepatide $2,883 to reach $240/mo
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.